ANI Pharmaceuticals (ANIP) Stock: Buy, Sell, or Hold?
$71.12
+0.03 (+0.04%)
▲
5d:
+2.15%
30d:
+1.37%
90d:
-7.08%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 05, 2026
0d
Protect ANIP Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (91%)
Quality Score
51/100
Position
OVERSOLD
30-Day Fair Range
$70.09 – $73.23
Position: OVERSOLD
Forward P/E & Valuation
7.0x
CHEAP
vs 7.9x historical avg
Wall Street Target
$105.22
+48.0% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$67.14 / $76.00
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: ANIP shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When ANIP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$106.07
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$65.86
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANIP is currently trading at $71.12, which is considered oversold relative to its 30-day fair value range of $70.09 to $73.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.0) compared to its historical average (7.9). Remarkably, the market is currently pricing in an annual earnings decline of 3.9% over the next few years. This pessimistic expectation contrasts with the company's recent 33.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ANIP is in a strong downtrend. Immediate support is located at $67.14, while resistance sits at $76.00.
Market Sentiment: ANIP scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $105.22 (+48.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANIP is in a strong downtrend. Immediate support is located at $67.14, while resistance sits at $76.00.
Market Sentiment: ANIP scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $105.22 (+48.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$70.09 -
$73.23
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Trading Range & Key Levels
30-Day Trading Range
$70.09 -
$73.23
Current vs Trading Range
OVERSOLD
Support Level
$67.14
Resistance Level
$76.00
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding ANIP? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.0% below Wall St target ($105.22)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
6.97
Wall Street Target
$105.22
(+48.0%)
Revenue Growth (YoY)
27.6%
Earnings Growth (YoY)
33.4%
Profit Margin
11.2%
Valuation Discount vs History
-3.9% cheaper
PE vs Historical
7.0 vs 7.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.9%
(market-implied from PE analysis)
1-Year Target
$68.32
(-4%)
2-Year Target
$65.65
(-8%)
3-Year Target
$63.09
(-11%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$71.54
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 7.3%)
$250.35
(+252%)
Base:
(SPY PE: 7.0, Growth: 7.3%)
$87.83
(+24%)
Bear:
(PE: 5.9, Growth: 7.3%)
$74.66
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 14.16 | Current EPS (TTM): $5.03
Bull Case
$156.75
(+121%)
Analyst growth 100.0%, PE expands to 15.6
Base Case
$142.50
(+100%)
Market implied 100.0%, PE stable at 14.2
Bear Case
$48.45
(-32%)
Severe decline -20.0%, PE contracts to 12.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.0 to 7.9
Stabilization Target:
$80.60
(+13.4%)
PE Expansion Potential:
+13.4%
Share ANIP Analysis
Share this live ANIP analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ANIP)
Neutral
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 5, 2026
Daily AI digest
AI Retail Discussion Summary:
ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics for approximately $560M, expanding its rare disease business with EMCITATE, a potential blockbuster treatment for MCT8 deficiency.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Advanced ANIP Option Strategies
Professional options setups generated by AI based on today's ANIP price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ANIP Research Pages